Country Club Bank Has $19.07 Million Holdings in Johnson & Johnson $JNJ

Country Club Bank decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,018 shares of the company’s stock after selling 2,665 shares during the quarter. Johnson & Johnson accounts for approximately 1.1% of Country Club Bank’s investment portfolio, making the stock its 18th largest position. Country Club Bank’s holdings in Johnson & Johnson were worth $19,073,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in JNJ. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. GFG Capital LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at $35,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $48,000. Finally, Vermillion & White Wealth Management Group LLC grew its position in Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after acquiring an additional 150 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Citigroup boosted their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $210.25.

Johnson & Johnson Trading Down 1.0%

NYSE:JNJ opened at $208.23 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The firm’s fifty day moving average is $197.78 and its 200-day moving average is $178.67. The firm has a market cap of $501.68 billion, a P/E ratio of 20.10, a P/E/G ratio of 2.28 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.